| Autor: |
Niazi, Mohammad, Ahlbom, Henrik, Bondarov, Patrik, Karlsson, Anna H., Hassan-Alin, Mohammed, Rydholm, Hans, Röhss, Kerstin |
| Předmět: |
|
| Zdroj: |
Basic & Clinical Pharmacology & Toxicology; Dec2005, Vol. 97 Issue 6, p351-354, 4p |
| Abstrakt: |
There are situations where the use of an oral proton pump inhibitors is not possible. In such situations an intravenous route is the preferred alternative. An intravenous formulation of esomeprazole has recently been developed. This study was designed to evaluate the pharmacokinetics and tolerability of single-dose intravenous esomeprazole using different rates of administration. The study was an open randomised, cross-over design in healthy male and female (n=24). Esomeprazole 40 mg intravenously was adminstrated as an infusion over 10, 15, 20 or 30 min., or esomeprazole 20 mg intravenously as an injection over 3 min. There was a wash-out period of at least 6 days between dose regimens. It was demonstrated that increasing the rate of intravenous infusion of esomeprazole 40 mg resulted in higher Cmax values (geometric means; 5.2–7.6 μmol/l), but the AUC values remained relatively constant (7.1–7.2 μmor/l). As expected esomeprazole 20 mg administered as a 3 min. intravenous injection had lower Cmax (3.6 μmol/l) and AUC (2.9 μmol.r/l) values than any of the infusions of esomeprazole 40 mg. Intravenous esomeprazole was well tolerated in this study. In conclusion, any variation in the infusion rate of esomeprazole 40 mg intravenously has little effect on the pharmacokinetics of esomeprazole in healthy volunteers, which provides flixibility in the choice of dosing regimens. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
